Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional

Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)

ClinicalTrials.gov ID: NCT00662740

Public ClinicalTrials.gov record NCT00662740. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

1-yr Study Comparing TioSal Combo Regimens Versus Single Agent Therapies (Spiriva HandiHaler and Salmeterol PE Capsule)

Study identification

NCT ID
NCT00662740
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Boehringer Ingelheim
Industry
Enrollment
220 participants

Conditions and interventions

Interventions

  • Tiotropium/Salmeterol QD Drug
  • Placebo Drug
  • Salmeterol Drug
  • Tiotropium/Salmeterol QD+ Salmeterol Drug
  • Tiotropium (Spiriva®) Drug

Drug

Eligibility (public fields only)

Age range
40 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 14, 2008
Primary completion
Nov 20, 2008
Completion
Nov 20, 2008
Last update posted
Aug 22, 2023

2008

United States locations

U.S. sites
20
U.S. states
13
U.S. cities
19
Facility City State ZIP Site status
1184.14.01013 Boehringer Ingelheim Investigational Site Boulder Colorado
1184.14.01018 Boehringer Ingelheim Investigational Site Wheat Ridge Colorado
1184.14.01006 Boehringer Ingelheim Investigational Site Winter Park Florida
1184.14.01003 Boehringer Ingelheim Investigational Site Coeur d'Alene Idaho
1184.14.01015 Boehringer Ingelheim Investigational Site South Bend Indiana
1184.14.01007 Boehringer Ingelheim Investigational Site Lafayette Louisiana
1184.14.01005 Boehringer Ingelheim Investigational Site Bangor Maine
1184.14.01020 Boehringer Ingelheim Investigational Site Edina Minnesota
1184.14.01009 Boehringer Ingelheim Investigational Site Burlington North Carolina
1184.14.01002 Boehringer Ingelheim Investigational Site Cincinnati Ohio
1184.14.01021 Boehringer Ingelheim Investigational Site Toledo Ohio
1184.14.01012 Boehringer Ingelheim Investigational Site East Providence Rhode Island
1184.14.01017 Boehringer Ingelheim Investigational Site Greenville South Carolina
1184.14.01008 Boehringer Ingelheim Investigational Site Spartanburg South Carolina
1184.14.01014 Boehringer Ingelheim Investigational Site Houston Texas
1184.14.01022 Boehringer Ingelheim Investigational Site Killeen Texas
1184.14.01001 Boehringer Ingelheim Investigational Site San Antonio Texas
1184.14.01010 Boehringer Ingelheim Investigational Site Temple Texas
1184.14.01011 Boehringer Ingelheim Investigational Site Richmond Virginia
1184.14.01019 Boehringer Ingelheim Investigational Site Richmond Virginia

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 52 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00662740, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 22, 2023 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00662740 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →